



NACL Industries Limited

Ref: NACL/SE/2023-24

January 25, 2024

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

Company Code: 524709

National Stock Exchange of India Ltd

Exchange Plaza, 5th Floor,
Plot No.C/1 G Block, Bandra- Kurla
Complex, Bandra, Mumbai – 400051

Symbol: NACLIND

Dear Sir/Madam,

Sub: Corrigendum to our ‘Outcome of the Board of Director’s Meeting’ dated January 23, 2024.

Ref: Regulations 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015- reg.

This has reference to our letter dated January 23, 2024 having subject line ‘Outcome of the Board of Director’s Meeting’ pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is to inform you that a clerical error was crept in the point no. (c) of the Outcome of the Board of Director’s Meeting where the designation of Dr.Biju Pillai is inadvertently mentioned as “*Head - R&D*” instead of “*Director - R&D*”.

The revised para in the letter shall be read as follows:

c) Designated Dr. Biju Pillai, Director - R&D, as Senior Management Personnel (SMP) of the Company with effect from January 23, 2024.

Hence the designation of Dr Biju Pillai shall stand corrected and read as *Director – R&D*, wherever appears in the aforesaid letter.

The revised **Annexure B** submitted pursuant to SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed herewith.



There are no other corrections to the Outcome of the Board of Director's Meeting filed with the Stock Exchanges on January 23, 2024.

You are requested to take the same on records.

Thanking you

for **NACL Industries Limited**



Satish Kumar Subudhi

Vice President-Legal & Company Secretary



Annexure – B**Designated Dr. Biju Pillai, Director - R&D, as Senior Management Personnel (SMP) of the Company:**

Sl. No.	Details of events that need to be provided	Information of such events
1)	Reasons for change.	Designated Dr. Biju Pillai, Director-R&D, as SMP of the Company with effect from January 23, 2024.
2)	Date and terms of appointment.	Date of appointment as SMP: January 23, 2024 Term of appointment - Not Applicable
3)	Brief Profile.	Dr. Biju Pillai is a PHD in Organic Chemistry. Dr. Biju Pillai is a seasoned R&D professional with an a impressive track record of about 24 years. He recently served as Director of Global Chemical R&D at Adama India, holding a concurrent position as a Whole Time Director on the Company's Board. Prior to this, Dr. Pillai honed his expertise across diverse pharmaceutical organizations, including Alembic Research Centre, Torrent Research Center, Macleods Pharmaceuticals, Glenmark Research Center, Orchid Chemicals and Pharmaceuticals, Cheminor Drugs and Dr.Reddy's Laboratories.
4)	Disclosure of relationship between Directors.	Dr. Biju Pillai is not related to any other Director of the Company.